Press Room

Event

AAPS 2021 PharmSci 360

Start
Sunday, October 17, 2021 - 00:00
End
Wednesday, October 20, 2021 - 00:00
Location: Philadelphia, USA
Booth Number: 1202
fully integrated solution provider for inhalation | Hovione

We are ready to safely return to AAPS PharmSci 360 in Philadelphia and we look forward to seeing you.

 

Schedule a meeting at the Hovione's booth (#1202) or online

Schedule a meeting button | Hovione
https://go.hovione.com/l/47122/2014-08-06/9grc

 

HOVIONE PRESENTATIONS AT AAPS

Join Hovione Scientists in their virtual oral presentations and poster abstracts and find out more about their latest research and innovation.

maria paisana Analytical Development Scientist | Hovione

 

Maria Paisana - Senior Analytical Scientist, Analytical Development Group

Presentation: Make it Flow: Can Ring Shear Tester Predict Flowability Through Hoppers?
Poster: Ring Shear Tester: The importance of Shear and Wall Friction Methodology for Arching Tendency Predictions

 

 

 
Luis Sobral Fellow Scientist R&D | Hovione

 

Luís Sobral - Fellow Scientist, R&D
Presentation: Modeling Chemical Reactions with Quantum Mechanics

 

Ricardo Gonçalves R&D Analytical Development | Hovione

Ricardo Gonçalves - Analytical Scientist, R&D Analytical Development
Presentation: Understanding Dry Powder Inhalers Formulations: Role of Surface Polarity of lactose mixtures

 

Beatriz Noriega-Fernandes Inhalation and Advanced Drug Delivery R&D | Hovione

 

Beatriz Noriega-Fernandes - Scientist, Inhalation and Advanced Drug Delivery Group, R&D
Poster: Spray-Dried Composite Formulation Containing DSPC for Lung Sustained Release

 

 
Luis Sousa R&D Analytical Development | Hovione

 

Luís Sousa - Senior Analytical Scientist, R&D Analytical Development
Poster: Evaluation of the Relaxation State of Amorphous Itraconazole Using Solution Calorimetry

 

From feasibility to commercial: Integrated Dry Powder Inhalation solutions to help bring inhaled medicines to patients

 
 

Hovione offers Customized high-performance APIs, Particle Engineering and Formulation along with a full range of highly specialized, innovative inhalation Devices. Our motto is Everything for Inhalation meaning great People, great Science and Technology combined with a strong Quality and Safety culture.

 

 

Let’s discuss your project together. 

 

Also in the Press Room

See All

Hovione is a global contract development and manufacturing organization (CDMO) company founded in Portugal in 1959. With approximately 2,400 team members worldwide, the company provides comprehensive services for drug substances, drug intermediates, and drug products in countries around the world. Japan in particular plays a very important role in Hovione's global strategy, and in 2017 it established a Japanese subsidiary in Osaka. The company plans to actively invest in further strengthening its organization and recruiting personnel. With development labs strategically located in Lisbon, Portugal, and New Jersey, USA, Hovione consistently provides superior solutions tailored to complex pharmaceutical challenges. Hovione is recognized globally for its scientific excellence, technological innovation, and customer-centric and integrated approach. Leveraging cutting-edge capabilities in chemical synthesis, particle engineering, and formulation development, the company supports its partners throughout the entire pharmaceutical life cycle.   Read the full article in Japanese Read the article translated in English   Visit the Yakuji Nippo online      

Press Clipping
Yakuji Nippo Magazine, 2 July 2025

Solving Complex Pharmaceutical Challenges

Jul 10, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping
Pharmiweb.com, 25 June 2025

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025

Also in Events

See All